drugset / Trial / NCT07186452

Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors

NCT07186452

Phase 1 Recruiting 18 enrolled Hansoh BioMedical R&D Company
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the effect of itraconazole on the pharmacokinetics of HS-20093 in patients with advanced solid tumors.

Timeline

Start
2025-09-23
Primary completion
2026-07-31
Completion
2026-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject HS-20093 Other / unclassified 8 mg/kg Intravenous
Subject Itraconazole Small molecule 200 mg Oral

Indications